Takeda
Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks
Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical
Takeda Faces $143M Loss After Epilepsy Drug Candidate Fails to Meet Expectations
Takeda, epilepsy drug, financial loss, pharmaceuticals, clinical trials
Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent
Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis
Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff
Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends
Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies
Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency
Takeda’s Orexin Narcolepsy Drug TAK-861 Poised for Phase III Trials After Promising Results
Takeda, TAK-861, narcolepsy, orexin receptor 2 agonist, Phase III trials, narcolepsy type 1, sleep disorders
Takeda Announces 641 Layoffs in Massachusetts Amid $900 Million Restructuring Campaign
Takeda, layoffs, Massachusetts, restructuring, pharmaceuticals, biotech, Cambridge, Lexington
Takeda Ventures into Molecular Glue Degraders with Degron Collaboration
Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.
Biopharma Downsizing Trends 2024: Major Companies Adjusting Workforce
Biopharma, layoffs, downsizing, workforce reduction, Evotec, Lyra Therapeutics, Takeda Pharmaceuticals, industry trends, 2024
WHO Approval for Takeda’s Dengue Vaccine: A Breakthrough in Global Health
WHO, Takeda, dengue vaccine, prequalification, global health, regulatory tracker, breakthrough, approval.